The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
Top Cited Papers
Open Access
- 15 August 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 19 (1), 3-14
- https://doi.org/10.1007/s10120-015-0526-8
Abstract
Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus.Keywords
Funding Information
- the Ministry of Health, Labor, and Welfare (Grant-in-Aid H26-cancer-general-089)
- The Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant-in-Aid for Scientific Research 26640110)
- National Cancer Centre Research and Development Fund (26-A-21)
- Yasuda Medical Foundation
This publication has 56 references indexed in Scilit:
- Clinical practice guidelines for patients with gastrointestinal stromal tumor in TaiwanWorld Journal of Surgical Oncology, 2012
- Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regionsAnnals Of Oncology, 2012
- Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132Annals of Surgical Oncology, 2011
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2011
- Succinate Dehydrogenase-Deficient GISTs: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 66 Gastric GISTs With Predilection to Young AgeThe American Journal of Surgical Pathology, 2011
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2008
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma GroupJournal of Clinical Oncology, 2007
- Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2006